Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 17, 2007

SynCo to Help Prosensa Advance its RNA-based Therapeutics for DMD

  • SynCo Bio Partners and Prosensa will collaborate in the formulation and fill of Prosensa’s RNA-based therapeutics for Duchenne muscular dystrophy (DMD).

    "SynCo is pleased to be working with Prosensa on this important clinical program for the life-saving treatment of DMD,” Pierre Warffemius, CEO of SynCo commented. “We aim to establish a long-term relationship with Prosensa to support their expanding portfolio of nucleic acid based therapeutics against neuromuscular disorders by providing high quality aseptic formulation and filling services."

  • You’re all set! Thank you for subscribing to GEN Highlights.